仁新(6696)子公司Belite再获国际大型基金1500万美元注资，今日股价跳空开高，一路往上攀升至148.5元，涨幅逼近5%左右。仁新表示，此次增资将充实Belite营运资金，专注LBS-008持续开发，以抢攻全球首款治疗STGD1与GA ...

Belite Bio (BLTE) announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the ...

Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused ...

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

JPMorgan Chase & Co. boosted its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) by 7,122.7% in the 3rd ...

EST Belite Bio (BLTE) files automatic mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover ...

Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous target of $57.00, while reiterating a Buy rating on the stock. The decision ...

分析师修订后的目标价反映了他们预计该药物的平均价格为50,000美元。他们指出，针对罕见遗传性疾病的治疗药物价格可能会显著高于他们的估计。这一更新后的估值并未考虑Tinlarebant在治疗干性年龄相关性黄斑变性（干性AMD）方面的潜力。

Belite Bio, Inc ( NASDAQ:BLTE ) is possibly approaching a major achievement in its business, so we would like to ...

Belite Bio, Inc (NASDAQ:BLTE) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Belite Bio, Inc, a clinical stage biopharmaceutical ...

Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

Monrovia – With the dawn of a new year, millions are setting health and fitness goals, only to find their resolutions fading by mid-year. QNET’s LifeQode BELITE 123 emerges as a trusted ally, offering ...